Developmental Therapeutics Committee

The Development Therapeutics Committee is in a unique position to facilitate the creation of new types of cancer treatment trials that personalize therapy using predictive biomarkers and drug targets. Its role in the Group is to:

  • Educate members about new treatments, drug targets, and biomarker technologies
  • Provide a platform for disseminating scientific concepts that arise within the 12 cancer-type-oriented committees and working groups in the Therapeutic Studies Program
  • Conduct correlative studies that explore variability in patients and tumors, with a treatment focus rather than a disease focus

The original concept for the landmark NCI-MATCH precision medicine cancer trial originated in this committee as part of a collaboration with researchers at the National Cancer Institute and throughout the National Clinical Trials Network (NCTN).

Developmental Therapeutics Committee



Chair

Dustin A. Deming, MD

University of Wisconsin/UW Carbone Cancer Center
Biography

Developmental Therapeutics CommitteeDevelopmental Therapeutics Committee
 

Genomics Subcommittee



Chair

Kristen Spencer, DO, MPH

New York University/NYU Langone Perlmutter Cancer Center
Biography

Developmental Therapeutics CommitteeDevelopmental Therapeutics Committee
 
 
ECOG-ACRIN Cancer Research Group